CartilaGen

Executive Summary

CartilaGen is a private, Phase 2 biopharmaceutical company focused on developing CG-001, a novel small molecule therapy for Post-Traumatic Osteoarthritis (PTOA) arising from ankle fractures and other traumatic skeletal injuries. PTOA is a significant unmet medical need, affecting a large patient population with no approved disease-modifying treatments. CG-001 targets oxidative stress, a key driver of cartilage degeneration following trauma. The company is based in San Diego, California, and was founded in 2018. With its lead program advancing in the clinic, CartilaGen represents an early-stage investment opportunity in the orthobiologics space. However, limited public information on financing, partnerships, or pipeline breadth contributes to uncertainty. The company's success hinges on positive clinical data and ability to secure funding for further development.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 clinical trial data readout for CG-001 in PTOA30% success
• H2 2026Potential strategic partnership or licensing deal for CG-00120% success
• Q1 2027FDA meeting or regulatory guidance for PTOA trial design50% success